Targeting EMT in cancer: Opportunities for pharmacological intervention

Trends in Pharmacological Sciences

Volumn 35, Issue 9, 2014, Pages 479-488

  Davis, Felicity M ^a   Stewart, Teneale A ^a   Thompson, Erik W ^b,c,d   Monteith, Gregory R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

cancer; cancer stem cells; Epithelial mesenchymal transition (EMT); invasion; mesenchymal epithelial transition (MET); metastasis; therapeutic targets; therapy resistance

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBRONECTIN; GROWTH ARREST SPECIFIC PROTEIN 6; INTERLEUKIN 6; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR TWIST; VIMENTIN; WITHAFERIN A;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL INVASION; CELL TRANSFORMATION; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HIGH RISK PATIENT; HUMAN; MESENCHYMAL EPITHELIAL TRANSITION; METASTASIS; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85010806419     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.06.006     Document Type: Review

References (147)

1. M.A. Nieto The ins and outs of the epithelial to mesenchymal transition in health and disease Annu. Rev. Cell Dev. Biol. 27 2011 347 376
2. J.P. Thiery et al. Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
3. E.D. Hay An overview of epithelio-mesenchymal transformation Acta Anat. (Basel) 154 1995 8 20
4. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J. Clin. Invest. 119 2009 1420 1428
5. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
6. A. Bonnomet et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer Oncogene 31 2011 3741 3753
7. A.J. Trimboli et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer Cancer Res. 68 2008 937 945
8. D. Sarrio et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype Cancer Res. 68 2008 989 997
9. E. Tomaskovic-Crook et al. Epithelial to mesenchymal transition and breast cancer Breast Cancer Res. 11 2009 213
10. M. Yu et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition Science 339 2013 580 584
11. N.P. Gunasinghe et al. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer Cancer Metastasis Rev. 31 2012 469 478
12. D. Tarin The fallacy of epithelial mesenchymal transition in neoplasia Cancer Res. 65 2005 5996 6000
13. A. Prat et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res. 12 2010 R68
14. Y. Shintani et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer Ann. Thorac. Surg. 92 2011 1794 1804
15. S. Thomson et al. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy Clin. Exp. Metastasis 25 2008 843 854
16. T. Arumugam et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res. 69 2009 5820 5828
17. W. Zhang et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells Biochem. Biophys. Res. Commun. 417 2012 679 685
18. S. Thomson et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res. 65 2005 9455 9462
19. H. Zhao et al. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines Mol. Cancer Ther. 11 2012 503 513
20. C.J. Creighton et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc. Natl. Acad. Sci. U.S.A. 106 2009 13820 13825
21. M. Rask-Andersen et al. Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
22. N. Marino et al. Breast cancer metastasis: issues for the personalization of its prevention and treatment Am. J. Pathol. 183 2013 1084 1095
23. S.A. Mani et al. The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 2008 704 715
24. K. Polyak, and R.A. Weinberg Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits Nat. Rev. Cancer 9 2009 265 273
25. R.D. Lester et al. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells J. Cell Biol. 178 2007 425 436
26. A. Yadav et al. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway Mol. Cancer Res. 9 2011 1658 1667
27. H-W. Lo et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression Cancer Res. 67 2007 9066 9076
28. S.K. Halder et al. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers Neoplasia 7 2005 509 521
29. F.M. Davis et al. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent Oncogene 33 2014 2307 2316
30. N. Balanis et al. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway J. Biol. Chem. 288 2013 17954 17967
31. H. Xiong et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition J. Biol. Chem. 287 2012 5819 5832
32. M. Colomiere et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas Br. J. Cancer 100 2009 134 144
33. J. Schust et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization Chem. Biol. 13 2006 1235 1242
34. K. Siddiquee et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. U.S.A. 104 2007 7391 7396
35. H. Li et al. Snail involves in the transforming growth factor beta1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells PLoS ONE 6 2011 e23322
36. B.J. van Denderen, and E.W. Thompson Cancer: the to and fro of tumour spread Nature 493 2013 487 488
37. A. Bonnomet et al. Epithelial-to-mesenchymal transitions and circulating tumor cells J. Mammary Gland Biol. Neoplasia 15 2010 261 273
38. N. Bednarz-Knoll et al. Plasticity of disseminating cancer cells in patients with epithelial malignancies Cancer Metastasis Rev. 31 2012 673 687
39. J. Yang et al. Mesenchymal to epithelial transition in sarcomas Eur. J. Cancer 50 2014 593 601
40. J.T. Thaiparambil et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation Int. J. Cancer 129 2011 2744 2755
41. G. Lahat et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies PLoS ONE 5 2010 e10105
42. R. Wang et al. Role of vimentin in smooth muscle force development Am. J. Physiol. Cell Physiol. 291 2006 C483 C489
43. H. Tanaka et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance Nat. Med. 16 2010 1414 1420
44. J. Yang et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 117 2004 927 939
45. H. Ling et al. MicroRNAs and other non-coding RNAs as targets for anticancer drug development Nat. Rev. Drug Discov. 12 2013 847 865
46. Z. Shi et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression Cancer Res. 73 2013 5519 5531
47. J.A. Sparano et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196 J. Clin. Oncol. 22 2004 4683 4690
48. C. Gjerdrum et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival Proc. Natl. Acad. Sci. U.S.A. 107 2010 1124 1129
49. S.J. Holland et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer Cancer Res. 70 2010 1544 1554
50. E. Marangoni et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts Br. J. Cancer 100 2009 918 922
51. P.B. Gupta et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
52. A. Jung et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation Am. J. Pathol. 159 2001 1613 1617
53. S. Vega et al. Snail blocks the cell cycle and confers resistance to cell death Genes Dev. 18 2004 1131 1143
54. H.J. Hugo et al. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells Breast Cancer Res. 15 2013 R113
55. C.L. Chaffer et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2 Cancer Res. 66 2006 11271 11278
56. C.A. Pinto et al. Breast cancer stem cells and epithelial mesenchymal plasticity: implications for chemoresistance Cancer Lett. 341 2013 56 62
57. J.H. Tsai et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis Cancer Cell 22 2012 725 736
58. O.H. Ocana et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1 Cancer Cell 22 2012 709 724
59. T. Celia-Terrassa et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells J. Clin. Invest. 122 2012 1849 1868
60. D. Sarrio et al. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties Stem Cells 30 2012 292 303
61. S. Liu et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts Stem Cell Reports 2 2014 78 91
62. M.K. Asiedu et al. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells Oncogene 33 2014 1316 1324
63. K. Vuoriluoto et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer Oncogene 30 2011 1436 1448
64. P.D. Dunne et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer Clin. Cancer Res. 20 2014 164 175
65. H.J. Lee et al. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma Carcinogenesis 35 2014 769 775
66. F.A. Duijkers et al. Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration Gene 521 2013 62 68
67. C.H. Lee et al. Axl is a prognostic marker in oral squamous cell carcinoma Ann. Surg. Oncol. 19 Suppl. 3 2012 S500 S508
68. J.B. Koorstra et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target Cancer Biol. Ther. 8 2009 618 626
69. A. Mishra et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer Mol. Cancer Res. 10 2012 703 712
70. S.J. Lee et al. Gene silencing of c-Met leads to brain metastasis inhibitory effects Clin. Exp. Metastasis 30 2013 845 854
71. S. Zhang et al. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer Cancer Biol. Ther. 15 2014 633 642
72. Y. Toiyama et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer Int. J. Cancer 130 2012 2912 2921
73. L.V. Rhodes et al. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-alpha)-positive breast cancer cells Exp. Cell Res. 317 2011 2573 2581
74. Y. Zhu et al. The effect of CXCR4 silencing on epithelial-mesenchymal transition related genes in glioma U87 cells Anat. Rec. (Hoboken) 296 2013 1850 1856
75. Y. Yoon et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models Cancer Res. 67 2007 7518 7524
76. E. Bertran et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta Cell. Signal. 21 2009 1595 1606
77. E. Bertran et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells Hepatology 58 2013 2032 2044
78. X. Li et al. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway Cancer Lett. 322 2012 169 176
79. Y. Jung et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis Nat. Commun. 4 2013 1795
80. A. Claperon et al. Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells Oncogene 31 2012 1376 1388
81. T. Sasaki et al. Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells Cancer Sci. 103 2012 1165 1171
82. D. Zhang et al. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer Clin. Cancer Res. 15 2009 6639 6648
83. G.H. Ha et al. TACC3 is essential for EGF-mediated EMT in cervical cancer PLoS ONE 8 2013 e70353
84. M.Y. Lee et al. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation Clin. Cancer Res. 14 2008 4743 4750
85. Y. Yan et al. Influence of epidermal growth factor receptor inhibitor AG1478 on epithelial-mesenchymal transition in endometrial carcinoma cells Int. J. Gynecol. Cancer 22 2012 1457 1462
86. S.B. Keysar et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer Cancer Res. 73 2013 3381 3392
87. J.H. Zuo et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin J. Cell. Biochem. 112 2011 2508 2517
88. S. La Monica et al. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification PLoS ONE 8 2013 e78656
89. J.C. Cheng et al. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS ONE 7 2012 e34071
90. M. Comamala et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells Br. J. Cancer 104 2011 989 999
91. P. Yue et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells Oncogene 31 2012 2309 2322
92. Z.G. Chang et al. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells Dig. Dis. Sci. 57 2012 1181 1189
93. H.W. Lue et al. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling PLoS ONE 6 2011 e27720
94. L. Rosano et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells Cancer Res. 65 2005 11649 11657
95. J. Peng et al. ROCK cooperated with ET-1 to induce epithelial to mesenchymal transition through SLUG in human ovarian cancer cells Biosci. Biotechnol. Biochem. 76 2012 42 47
96. L. Rosano et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells Clin. Cancer Res. 17 2011 2350 2360
97. W.W. Chang et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors Breast Cancer Res. 15 2013 R39
98. A. Vazquez-Martin et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations Sci. Rep. 3 2013 2560
99. P. Dasgupta et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines Int. J. Cancer 124 2009 36 45
100. P.L. Wei et al. Nicotine enhances colon cancer cell migration by induction of fibronectin Ann. Surg. Oncol. 18 2011 1782 1790
101. P.L. Wei et al. Tobacco-specific carcinogen enhances colon cancer cell migration through alpha7-nicotinic acetylcholine receptor Ann. Surg. 249 2009 978 985
102. Y.C. Lien et al. Nicotine promotes cell migration through alpha7 nicotinic acetylcholine receptor in gastric cancer cells Ann. Surg. Oncol. 18 2011 2671 2679
103. S. Suman et al. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells Br. J. Cancer 109 2013 2587 2596
104. X.Q. Wang et al. Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma Int. J. Cancer 131 2012 E163 E172
105. M. Xie et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells J. Cell. Biochem. 113 2012 1501 1513
106. M. Xie et al. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo Eur. J. Cancer 49 2013 3559 3572
107. J. Kang et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines J. Biol. Chem. 288 2013 27343 27357
108. Y. Matsuno et al. Notch signaling mediates TGF-beta1-induced epithelial-mesenchymal transition through the induction of Snai1 Int. J. Biochem. Cell Biol. 44 2012 776 789
109. Z.W. Wang et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells Is linked with activation of the Notch signaling pathway Cancer Res. 69 2009 2400 2407
110. C. Gungor et al. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer Cancer Res. 71 2011 5009 5019
111. Z. Zhang et al. Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis Am. J. Pathol. 177 2010 1459 1469
112. F. Yu et al. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells J. Biol. Chem. 287 2012 465 473
113. F.M. Davis et al. Remodeling of purinergic receptor-mediated Ca(2+) signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells PLoS ONE 6 2011 e23464
114. Y.A. Yoo et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer Cancer Res. 71 2011 7061 7070
115. J. Lei et al. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner Mol. Cancer 12 2013 66
116. R. Nanta et al. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rgamma null mice by regulating Bmi-1 and microRNA-128 Oncogenesis 2 2013 e42
117. R. Gupta et al. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells Int. J. Oncol. 38 2011 733 744
118. Z. Adhim et al. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines Br. J. Cancer 105 2011 393 402
119. C. Bocca et al. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness Expert Opin. Ther. Targets 18 2014 121 135
120. M. Dovizio et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells Mol. Pharmacol. 84 2013 25 40
121. A. Kirane et al. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib Carcinogenesis 33 2012 1639 1646
122. K.W. Hsu et al. MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2 Mol. Biol. Cell 20 2009 5127 5137
123. O.O. Ogunwobi et al. Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma J. Gastroenterol. Hepatol. 27 2012 566 578
124. O.O. Ogunwobi, and C. Liu Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways Clin. Exp. Metastasis 28 2011 721 731
125. A. Kirane et al. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer Clin. Cancer Res. 18 2012 5031 5042
126. M.D. Amatangelo et al. c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer Carcinogenesis 33 2012 1965 1975
127. M.P. Ponnusamy et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells Oncogene 29 2010 5741 5754
128. X. Yang et al. Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells Cell Death Dis. 4 2013 e735
129. J. Zhu et al. Downregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cells Cell. Signal. 24 2012 1323 1332
130. Y. Matsui et al. The importance of integrin-linked kinase in the regulation of bladder cancer invasion Int. J. Cancer 130 2012 521 531
131. I. Serrano et al. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFbeta-1-induced epithelial-mesenchymal transition (EMT) Oncogene 32 2013 50 60
132. S.L. Lee et al. Functional role of mTORC2 versus integrin-linked kinase in mediating Ser473-Akt phosphorylation in PTEN-negative prostate and breast cancer cell lines PLoS ONE 8 2013 e67149
133. T.R. McPhee et al. Integrin-linked kinase regulates E-cadherin expression through PARP-1 Dev. Dyn. 237 2008 2737 2747
134. Y. Xing et al. Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition Exp. Cell Res. 319 2013 2058 2072
135. M.W. Hance et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer J. Biol. Chem. 287 2012 37732 37744
136. C.Y. Lin et al. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition Cancer Sci. 102 2011 815 827
137. J. Ryu et al. Cross-regulation between protein L-isoaspartyl O-methyltransferase and ERK in epithelial mesenchymal transition of MDA-MB-231 cells Acta Pharmacol. Sin. 32 2011 1165 1172
138. X.D. Zhou, and Y.M. Agazie Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells Cell Death Differ. 15 2008 988 996
139. M. Shao et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase Cancer Res. 69 2009 9192 9201
140. C.Y. Lin et al. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells Mol. Cancer 10 2011 87
141. H. Shen et al. Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7 Mol. Biol. Rep. 36 2009 653 659
142. V. Lopez, and S.L. Kelleher Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells Exp. Cell Res. 316 2010 366 375
143. L. Zhao et al. LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway Biochem. Biophys. Res. Commun. 363 2007 82 88
144. R. Shen et al. Negative correlation of LIV-1 and E-cadherin expression in hepatocellular carcinoma cells PLoS ONE 8 2013 e56542
145. J. Unno et al. LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells Int. J. Oncol. 35 2009 813 821
146. H.E. Zhau et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model Clin. Exp. Metastasis 25 2008 601 610
147. W. Lai et al. KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer Med. Oncol. 30 2013 566